SavedAdd your journal

Journals / Kulak Burun Boğaz İhtisas Dergisi / 2008 / Cilt: 18 - Sayı: 4

Early evaluation of auditory dysfunction in patients with type 2 diabetes mellitus

Tip 2 diyabetli hastalarda işitsel fonksiyon bozukluklarının erken dönemde değerlendirilmesi

İbrahim ALADAĞ
SEMİHA GÜLSÜM KURT
Ahmet EYİBİLEN
MEHMET GÜVEN
ÜNAL ERKORKMAZ
Pages
203–210
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our results suggest that type 2 diabetes mellitus may lead to auditory dysfunction of cochlear and retrocochlear origin, and that microangiopathy, neuropathy, and poor metabolic control have adverse effects on auditory function.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We investigated auditory dysfunction in type 2 diabetic patients with normal hearing.
📊
Key Findings & Data:Patients and Methods: Forty patients (22 females; 18 males; mean age 55 years; range 32 to 76 years) with type 2 diabetes were examined by distortion product otoacoustic emissions (DPOAE) and auditory brainstem responses (ABR).
💡
Conclusion & Impact:Conclusion: Our results suggest that type 2 diabetes mellitus may lead to auditory dysfunction of cochlear and retrocochlear origin, and that microangiopathy, neuropathy, and poor metabolic control have adverse effects on auditory function.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Olgu-kontrol çalışmaları · Diabetik anjiyopatiler · İşitme yolları

Abstract

Objectives: We investigated auditory dysfunction in type 2 diabetic patients with normal hearing. Patients and Methods: Forty patients (22 females; 18 males; mean age 55 years; range 32 to 76 years) with type 2 diabetes were examined by distortion product otoacoustic emissions (DPOAE) and auditory brainstem responses (ABR). The patients were evaluated with respect to disease duration, microangiopathy, peripheral neuropathy, and metabolic control. The results were compared with those of 22 healthy controls. Results: Compared to controls, diabetic subjects had decreased DPOAE amplitudes at all frequencies, being significant at 4 kHz (p=0.011); ABR recordings showed a significant difference only in the III-V interwave interval latency (p=0.042). In the diabetic group, poor metabolic control was associated with significantly decreased DPOAE amplitudes at 4 kHz (p=0.046) and 8 kHz (p=0.020); the presence of microangiopathy was associated with prolonged ABR I-V interwave latency (p=0.039); and neuropathy was associated with decreased DPOAE amplitudes at 0.75 kHz (p=0.022), 1 kHz (p=0.019), and 3 kHz (p=0.049), and ABR differences in the absolute latency of wave III (p=0.007) and the I-III interwave latency (p=0.023). The duration of disease did not affect auditory function (p>0.05). Conclusion: Our results suggest that type 2 diabetes mellitus may lead to auditory dysfunction of cochlear and retrocochlear origin, and that microangiopathy, neuropathy, and poor metabolic control have adverse effects on auditory function.

Özet

Amaç: Normal işiten tip 2 diyabetli hastalarda ortaya çıkabilecek işitsel fonksiyon bozuklukları araştırıldı. Hastalar ve Yöntemler: Tip 2 diyabet tanılı 40 hasta (22 kadın; 18 erkek; ort. yaş 55; dağılım 32-76) distorsiyon ürünü otoakustik emisyonlar (DPOAE) ve işitsel beyin sapı yanıtları (ABR) ile araştırıldı. Tüm olgular hastalık süresi, mikroanjiyopati ve periferik nöropati varlığı ve metabolik kontrol açısından değerlendirildi. Sonuçlar, işitmesi normal ve diyabeti olmayan 22 kişilik kontrol grubuyla karşılaştırıldı. Bulgular: Kontrol grubuyla karşılaştırıldığında, diyabetli olgularda DPOAE düzeyleri, 4 KHz’de anlamlı olmak üzere (p=0.011), tüm frekanslarda daha zayıf bulundu; ABR’de ise, III-V dalgalar arası latans farklı idi (p=0.042). Metabolik kontrolü kötü olan olgularda DPOAE düzeylerinde (4 kHz için p=0.046; 8 kHz için p=0.020) anlamlı azalma, mikroanjiyopatisi olan olgularda ABR I-V dalgalar arası latansta uzama (p=0.039), nöropatisi olan olgularda ise hem DPOAE seviyelerinde (0.75 kHz için p=0.022; 1 kHz için p=0.019; 3 kHz için p=0.049) hem de ABR III dalga mutlak latansı (p=0.007) ve I-III dalgalar arası latansta (p=0.023) anlamlı farklılık görüldü. Hastalık süresi işitsel fonksiyon bozukluğu üzerine etkili bulunmadı (p>0.05). Sonuç: Bulgularımız, tip 2 diyabetin, koklear ve retrokoklear seviyede işitsel fonksiyonlarda bozulmaya yol açtığını; ayrıca, mikroanjiyopati, nöropati ve hastalığın metabolik kontrol derecesinin de bu bozulmada etkili olabileceğini göstermektedir

🔖

Cite This Article

ALADAĞ, İ., KURT, S. G., EYİBİLEN, A., GÜVEN, M., ERKORKMAZ, Ü. (2008). Early evaluation of auditory dysfunction in patients with type 2 diabetes mellitus. Kulak Burun Boğaz İhtisas Dergisi, Cilt: 18 - Sayı: 4, 203–210. https://ajindex.com/articles/342864

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Taylor IG, Irwin J. Some audiological aspects of diabetes mellitus. J Laryngol Otol 1978;92:99-113
  2. Lisowska G, Namysłowski G, Morawski K, Strojek K. Early identification of hearing impairment in patients with type 1 diabetes mellitus. Otol Neurotol 2001; 22:316-20
  3. Axelsson A, Fagerberg SE. Auditory function in diabetics. Acta Otolaryngol 1968;66:49-64
  4. Jorgensen MB. The inner ear in diabetes mellitus. Histological studies. Arch Otolaryngol 1961;74:373-81
  5. Jorgensen MB, Buch NH. Studies on inner-ear function and cranial nerves in diabetics. Acta Otolaryngol 1961;53:350-64
  6. Friedman SA, Schulman RH, Weiss S. Hearing and diabetic neuropathy. Arch Intern Med 1975;135:573-6
  7. Reske-Nielsen E, Lundbaek K, Gregersen G, Harmsen A. Pathological changes in the central and peripheral nervous system of young long-term diabetics. The terminal neuro-muscular apparatus. Diabetologia 1970;6: 98-103
  8. DeJong RN. CNS manifestations of diabetes mellitus. Postgrad Med 1977;61:101-7
  9. Oh SJ. Normal values for common nerve conduction tests. In: Oh SJ, editor. Clinical electromyography: nerve conduction studies. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 86-106
  10. Feldman EL, Stevens MJ. Clinical testing in diabetic peripheral neuropathy. Can J Neurol Sci 1994;21:S3-7
  11. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, et al. Total neuropathy score: validation and reliability study. Neurology 1999;53:1660-4
  12. Orts Alborch M, Morant Ventura A, Garcia Callejo J, Perez del Valle B, Lorente R, Marco Algarra J. The study of otoacoustic emissions in diabetes mellitus. Acta Otorrinolaringol Esp 1998;49:25-8. [Abstract] 13. Di Leo MA, Di Nardo W, Cercone S, Ciervo A, Lo Monaco M, Greco AV, et al. Cochlear dysfunction in IDDM patients with subclinical peripheral neuropathy. Diabetes Care 1997;20:824-8
  13. Simoncelli C, Ricci G, Molini E, Scionti L, Giommetti S, Pennacchi A, et al. Evoked acoustic oto-emissions in patients with diabetes mellitus. Ann Otolaryngol Chir Cervicofac 1993;110:255-8. [Abstract] 15. Park MS, Park SW, Choi JH. Distortion product otoacoustic emissions in diabetics with normal hearing. Scand Audiol Suppl 2001;52:148-51
  14. Erdem T, Ozturan O, Miman MC, Ozturk C, Karatas E. Exploration of the early auditory effects of hyperlipoproteinemia and diabetes mellitus using otoacoustic emissions. Eur Arch Otorhinolaryngol 2003;260:62-6
  15. Makishima K, Tanaka K. Pathological changes of the inner ear a